Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ReShape Dual Balloon Enters U.S. Market, Headlining Week Of Obesity Device News

This article was originally published in The Pink Sheet Daily

Executive Summary

It was a banner day for minimally invasive weight-loss devices July 28. FDA approved ReShape Medical's intragastric balloon and Aspire Bariatrics submitted an application for its AspireAssist aspiration therapy system for obesity. Two days later, GI Dynamics announced the termination of a pivotal study for its Endobarrier device.

Advertisement

Related Content

GI Dynamics Terminates Pivotal Endobarrier Trial Based On Safety Data
Obesity Devices: The Next Wave
Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions
FDA Weighs Patients' Risk Tolerance in Approving Obesity Device
ReShape Duo Delivers Weight Loss In Sham-Controlled Pivotal Trial

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel